<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167908</url>
  </required_header>
  <id_info>
    <org_study_id>ETH018-01D</org_study_id>
    <secondary_id>HSC 00-0885</secondary_id>
    <nct_id>NCT00167908</nct_id>
  </id_info>
  <brief_title>Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer</brief_title>
  <official_title>Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Amifostine provides additional protection&#xD;
      of salivary gland function over that achieved with IMRT alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary function at 6 months and yearly compared to pre-treatment salivary function</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and regional tumor control</measure>
  </secondary_outcome>
  <enrollment>27</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyol (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed squamous cell cancer of the head and neck&#xD;
&#xD;
          -  Eligible sites: oral cavity, oropharynx, hypopharynx, larynx.&#xD;
&#xD;
          -  Patients requiring postoperative IMRT.&#xD;
&#xD;
          -  KPS &gt; 70%.&#xD;
&#xD;
          -  Patient has signed specific protocol consent prior to registration.&#xD;
&#xD;
          -  Calcium test within normal limits.&#xD;
&#xD;
          -  No previous malignancy except for non-melanoma skin cancer or cancer not of head and&#xD;
             neck and controlled for at least 5 years.&#xD;
&#xD;
          -  Labs completed with 30 days of registration (CBC &amp; platelet, Ca++, Alk phos, SGOT,&#xD;
             Bili, albumin) CXR and CT simulation.&#xD;
&#xD;
          -  Liver CT if alk phos, SGOT, or bili elevated.&#xD;
&#xD;
          -  Bone scan if elevated alk phos&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease.&#xD;
&#xD;
          -  Patient using Salagen or concurrent chemotherapy.&#xD;
&#xD;
          -  Previous XRT for head and neck tumors.&#xD;
&#xD;
          -  Active untreated infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wade Thorstad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wade Thorstad, MD</name_title>
    <organization>Washington University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

